BR9811956A - Naftiridinonas para a inibição de proteìna tirosina cinase e de proliferação celular mediada por cinase de ciclo de célula - Google Patents

Naftiridinonas para a inibição de proteìna tirosina cinase e de proliferação celular mediada por cinase de ciclo de célula

Info

Publication number
BR9811956A
BR9811956A BR9811956-7A BR9811956A BR9811956A BR 9811956 A BR9811956 A BR 9811956A BR 9811956 A BR9811956 A BR 9811956A BR 9811956 A BR9811956 A BR 9811956A
Authority
BR
Brazil
Prior art keywords
kinase
naphthyridinones
inhibition
cell cycle
protein tyrosine
Prior art date
Application number
BR9811956-7A
Other languages
English (en)
Other versions
BR9811956B1 (pt
Inventor
Mark Robert Barvian
William Alexander Denny
Ellen Myra Dobrusin
James Marino Hamby
Howard Daniel Hollis Showalter
Andrew Mark Thompson
Roy Thomas Winters
Zhipei Wu
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR9811956A publication Critical patent/BR9811956A/pt
Publication of BR9811956B1 publication Critical patent/BR9811956B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Patente de Invenção: <B>"NAFTIRIDINONAS PARA A INIBIçãO DE PROTEìNA TIROSINA CINASE E DE PROLIFERAçãO CELULAR MEDIADA POR CINASE DE CICLO DE CéLULA"<D>. Naftiridinonas da fórmula (I) são inibidores de PTKs e de cinases de ciclo de célula, e são úteis no tratamento de proliferação celular. Os compostos são especialmente úteis no tratamento de câncer, aterosclerose, restenose e psoríase.
BRPI9811956-7A 1997-08-20 1998-08-13 naftiridinonas e composição farmacêutica compreendendo as mesmas. BR9811956B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5674697P 1997-08-20 1997-08-20
PCT/US1998/016848 WO1999009030A1 (en) 1997-08-20 1998-08-13 Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation

Publications (2)

Publication Number Publication Date
BR9811956A true BR9811956A (pt) 2000-08-15
BR9811956B1 BR9811956B1 (pt) 2010-06-01

Family

ID=22006345

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9811956-7A BR9811956B1 (pt) 1997-08-20 1998-08-13 naftiridinonas e composição farmacêutica compreendendo as mesmas.

Country Status (13)

Country Link
US (1) US6150359A (pt)
EP (1) EP1003745B1 (pt)
JP (1) JP4965021B2 (pt)
KR (1) KR20010023089A (pt)
AT (1) ATE286053T1 (pt)
AU (1) AU742999B2 (pt)
BR (1) BR9811956B1 (pt)
CA (1) CA2291222C (pt)
DE (1) DE69828408T2 (pt)
ES (1) ES2235353T3 (pt)
NZ (1) NZ502704A (pt)
WO (1) WO1999009030A1 (pt)
ZA (1) ZA987491B (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1801112A1 (en) * 1998-05-26 2007-06-27 Warner-Lambert Company LLC Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
YU73300A (sh) * 1998-05-26 2003-08-29 Warner-Lambert Company Biciklični pirimidini i biciklični 3,4-dihidropirimidini kao inhibitori ćelijske proliferacije
ES2259079T3 (es) * 2001-01-19 2006-09-16 Smithkline Beecham Corporation Inhibidores de la actividad cinasa del receptor tie2 para tratar enfermedades angiogenicas.
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
WO2002068419A1 (fr) * 2001-02-26 2002-09-06 Tanabe Seiyaku Co., Ltd. Derive de pyridopyrimidine ou naphthyridine
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
US20040005567A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of cyclin-dependent kinase 4 expression
IL164799A0 (en) 2002-04-25 2005-12-18 Univ Connecticut Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
PA8577501A1 (es) * 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
DE60316581T2 (de) * 2002-08-06 2008-07-03 F. Hoffmann-La Roche Ag 6-alkoxypyridopyrimidine als inhibitoren der p-38-map-kinase
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
DE602004021558D1 (de) * 2003-01-17 2009-07-30 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
MXPA06003996A (es) * 2003-10-08 2006-07-05 Irm Llc Compuestos y composiciones como inhibidores de la proteina cinasa.
EP1699477A2 (en) * 2003-12-11 2006-09-13 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
US7211576B2 (en) 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
JP2009507924A (ja) * 2005-09-14 2009-02-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｃ−ｆｍｓキナーゼ阻害剤としての５−オキソ−５，８−ジヒドロ−ピリド−ピリミジン
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
WO2008055842A1 (en) * 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Substituted 6-phenyl-pyrido [2,3-d] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
US20100173426A1 (en) * 2006-12-19 2010-07-08 Johnson Faye M Biomaker identifying the reactivation of stat3 after src inhibition
WO2008104473A2 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
EA018551B1 (ru) 2008-02-22 2013-08-30 Айрм Ллк ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-KIT И PDGFR
CN101684119B (zh) * 2008-09-27 2012-11-28 中国科学院上海药物研究所 5,8-二取代-1,6-二氮杂萘-7-羰酰胺类化合物及其制备方法、组合物和用途
ES2685171T3 (es) 2010-06-14 2018-10-05 The Scripps Research Institute Reprogramación de células a un nuevo destino
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
PT3176170T (pt) 2012-06-13 2019-02-05 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
WO2014052365A1 (en) * 2012-09-26 2014-04-03 Mannkind Corporation Multiple kinase pathway inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PE20152033A1 (es) 2013-04-19 2016-01-21 Incyte Holdings Corp Heterociclos bicicliclos como inhibidores de fgfr
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
BR112019012176A2 (pt) * 2016-12-16 2019-11-05 Cstone Pharmaceuticals composto, sal farmaceuticamente aceitável do mesmo ou isômero do mesmo, uso dos mesmos e composição farmacêutica
CN108264511B (zh) * 2017-01-03 2021-04-13 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和其在医药上的用途
WO2018213219A1 (en) * 2017-05-15 2018-11-22 University Of Houston System Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN112867716A (zh) 2018-05-04 2021-05-28 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
CA3099116A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
WO2020106308A1 (en) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
US20230048132A1 (en) * 2018-12-28 2023-02-16 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CA3137869A1 (en) * 2019-05-16 2020-11-19 Gregory Cuny Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3156268A1 (en) * 2019-10-01 2021-04-08 Goldfinch Bio, Inc. CDK5 SUBSTITUTE 1,6-NAPHTYRIDINE INHIBITORS
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
AR122928A1 (es) * 2020-07-10 2022-10-19 Goldfinch Bio Inc 1,6-naftiridinas sustituidas inhibidoras de cdk5
WO2022236319A1 (en) * 2021-05-07 2022-11-10 Enliven Therapeutics, Inc. Naphthyridone compounds for inhibition of raf kinases and/or bcr-abl tyrosine kinases
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) * 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
US3639401A (en) * 1969-07-28 1972-02-01 Parke Davis & Co 6-aryl-2 7-bis((trialkylsilyl)amino)pyrido (2 3-d)pyrimidine compounds
US4271164A (en) * 1979-04-16 1981-06-02 Warner-Lambert Company 6-Substituted-arylpyrido[2,3-d]pyrimidin-7-amines and derivatives
SG64322A1 (en) * 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
FR2706898B1 (pt) * 1993-06-25 1995-09-08 Union Pharma Scient Appl
GEP20012444B (en) * 1994-11-14 2001-05-25 Warner Lambert Company Us 6-Aryl Pyrido[2,3-d]Pyrimidines and Naphthyridines, Pharmaceutical Composition on Their Basis and Application for Inhibiting Cellular Proliferation
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation

Also Published As

Publication number Publication date
EP1003745B1 (en) 2004-12-29
ATE286053T1 (de) 2005-01-15
BR9811956B1 (pt) 2010-06-01
JP4965021B2 (ja) 2012-07-04
ZA987491B (en) 1999-04-21
ES2235353T3 (es) 2005-07-01
CA2291222C (en) 2004-03-30
NZ502704A (en) 2002-06-28
AU742999B2 (en) 2002-01-17
DE69828408D1 (de) 2005-02-03
KR20010023089A (ko) 2001-03-26
AU8828998A (en) 1999-03-08
CA2291222A1 (en) 1999-02-25
DE69828408T2 (de) 2005-12-08
EP1003745A1 (en) 2000-05-31
US6150359A (en) 2000-11-21
JP2001515078A (ja) 2001-09-18
WO1999009030A1 (en) 1999-02-25

Similar Documents

Publication Publication Date Title
BR9811956A (pt) Naftiridinonas para a inibição de proteìna tirosina cinase e de proliferação celular mediada por cinase de ciclo de célula
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
DK0888353T3 (da) N-7-Heterocyclyl-pyrrolo[2,3-d]pyrimidiner og deres anvendelse
IL136738A0 (en) Inhibition of p38 kinase activity using substituted heterocyclic ureas
HK1031832A1 (en) Inhibition of p38 kinase activity using aryl and heteroaryl substituted heterocyclic ureas
AP2000001996A0 (en) Heterocyclic inhibitors of P38.
BR9609617B1 (pt) derivados de 7h-pirrol[2,3-d]pirimidina, e composição farmacêutica.
TR200103216T2 (tr) Pirimidinon bileşimleri
ATE296799T1 (de) P38-inhibitoren
MY117696A (en) INHIBITORS OF p38
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
MX9101913A (es) Derivados de quinazolinas para potenciar la actividad antitumoral
ES2151467T1 (es) Inhibicion de la actividad de la quinasa p38 por aril-ureas.
HK1051005A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
ATE256673T1 (de) Chirale phenyldihydrofuranone als pde-iv inhibitoren
MY127675A (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
ES2181160T3 (es) Derivados de 1,4-dihidropiridina y su utilizacion en terapia.
DE59805112D1 (de) Chimäre oligonucleotide und ihre verwendung

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: C07D 471/02, A61K 31/4375, A61K 31/498, A61K 31/4985, A61P 9/08, A61P 9/10, A61P 17/06, A61P 35/00, A61P 43/00

Ipc: C07D 471/02 (2008.01), A61K 31/4375 (2008.01), A61

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/06/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2266 DE 10-06-2014 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.